A review of rabeprazole in the treatment of acid-related diseases.

摘要: Rabeprazole is a proton pump inhibitor. Pharmacodynamic data show rabeprazole can achieve optimal acid suppression since the first administration and maintain this advantage in following days of therapy. Moreover, has highest pKa (~ 5.0, pH at which drug becomes 50% protonated), hence molecule be activated higher levels much faster than other PPIs. Due to its peculiar catabolic pathway, ie, prevalent metabolism through non-enzymatic less susceptible influence genetic polymorphisms for CYP2C19, resulting minor influences on pharmacokinetics pharmacodynamics. In terms clinical efficacy, 20 mg uid or 10 bid produced healing rates 8 weeks similar those obtained with omeprazole erosive esophagitis patients, NERD patients doses are equivalent both better placebo 2 4 weeks. To prevent symptomatic relapse, on-demand strategy daily appears ideal, due rapidity onset; results have documented superiority over placebo. Continuous treatment, however, up 5 years, seems therapy, particularly esophagitis. It debated whether latter halved (10 mg) really full dose (20 mg). been used success treatment some atypical GERD manifestations, such as dysphagia associated GERD, GERD-related asthma chest-pain, therapy Barrett’s esophagus. Finally, achieves Helicobacter pylori eradication compared lansoprazole when co-administrated low high antibiotics (amoxicillin clarithromycin). addition, mg/bid) may effective eradicating pathogen